Back to companies

BrightGene Bio-Medical Technology Co Ltd: Overview

BrightGene Bio-Medical Technology Co Ltd (BrightGene) is a biopharmaceutical company that manufacturing, research and develop of generic drugs. The company’s pipeline products include posaconazole, oseltamivir phosphate, orivancin, fidaxomycin, agatroban, fondaparinux, acarbose, iron supplements, trabectidine, pemetrexed disodium intermediate, eribulin mesylate, midotolin, everolimus and pimecrolimus, among others. Its veterinary drugs includes seramectin, telavancin hydrochloride, emodes, doramectin and dalbavancin. The company develops products in the therapeutic areas of cardiology, oncology, antibacterial, antifungal and veterinary. BrightGene is headquartered in Suzhou, Jiangsu, China.

Headquarters China

Address Building C25-28, No.218 Xinghu Road, Sip, Suzhou, Jiangsu, 215123


Telephone 86 512 62620988

No of Employees 910

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange 688166 (SHA)

Revenue (2021) $163.2M 34% (2021 vs 2020)

EPS XXX

Net Income (2021) XXX 43.6% (2021 vs 2020)

Market Cap* $1.2B

Net Profit Margin (2021) XXX 7.2% (2021 vs 2020)

* As of and is in US$

Access premium data and analytics for BrightGene Bio-Medical Technology Co Ltd

13+

Pipeline Drugs

Identify which of BrightGene Bio-Medical Technology Co Ltd’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

12+

Clinical Trials

Determine BrightGene Bio-Medical Technology Co Ltd go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

9

Marketed Drugs

Understand BrightGene Bio-Medical Technology Co Ltd’s commercialized product portfolio to stay one step ahead of the market.

8

Install Base

Install Base provides a holistic and a granular view of the IT product/service deployments from leading vendors. Explore IT infrastructure categories, solution and product/service areas deployed by a prospect.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on BrightGene Bio-Medical Technology Co Ltd’s likely spend across technology areas enabling you to understand the digital strategy.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products Services
Anti-Infection Products Research and Development
Iron Supplements
Antitumor Drugs
XXX
XXX
XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2021 Contracts/Agreements In September, the company signed a co-development agreement with GeneQuantum Healthcare for antibody immune agonist conjugate (AIAC), GQ1007.
2021 Contracts/Agreements In June, the company and Oncogen Pharma signed an agreement to develop, manufacture, market, and distribute Generic products for the US market.
2020 Contracts/Agreements In April, the company secured a contract, worth US$8.5 million, from US pharmaceutical firm to produce a generic version of the breast cancer eribulin.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters BrightGene Bio-Medical Technology Co Ltd Ascletis Pharma Inc China Pharma Holdings Inc Changzhou Sunlight Pharmaceutical Co Ltd Crystal Pharmatech Co Ltd
Headquarters China China China China United States of America
City Suzhou Hangzhou Haikou Changzhou Cranbury
State/Province Jiangsu Zhejiang Hainan Jiangsu New Jersey
No. of Employees 910 315 236 - -
Entity Type Public Public Public Private Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Jiandong Yuan Chairman; General Manager Executive Board 2015 52
Zou Yuanlai Director - Finance Senior Management 2015 51
Wang Zhengye Deputy General Manager Senior Management 2017 52
Ding Nan Secretary Senior Management 2021 31
Li Kai Deputy General Manager Senior Management 2015 46
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company Analytics

Contact the team or request a demo to find out how our data can drive your business forward

Why are you leaving?